Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone Treatment
Authors:
- George L. BarnesGBGeorge L. Barnes
- Sanjeev KakarSKSanjeev Kakar
- Siddarth VoraSVSiddarth Vora
- Elise F. MorganEMElise F. Morgan
- Louis C. GerstenfeldLGLouis C. Gerstenfeld
- Thomas A. EinhornTEThomas A. Einhorn
- 1 February 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 90 (Supplement) , 120-127
Abstract
Over the past several years, there has been an increasing interest in the biology of bone repair and potential technologies for enhancing fracture-healing. Part of this interest is derived from the growing age of the population and the recognition that increased age carries an increased risk of complications after fracture. Although use of locally implanted or injected growth factors has received the most attention, systemic treatments for the enhancement of bone repair, especially for situations in which bone repair may be diminished or delayed, are now under investigation. Since the approval of parathyroid hormone (PTH) as an anabolic treatment for osteoporosis, there has been an increasing interest in other potential clinical uses for this compound in musculoskeletal conditions. It is now widely recognized that PTH administration is an effective therapy to increase bone mineral density and prevent fractures in patients with osteoporosis. More recently, a growing body of evidence has supported the conclusion that PTH will also be an effective anabolic therapy for the enhancement of bone repair after fracture. This review focuses on the recent research demonstrating the potential of PTH in the management of bone repair in a number of fracture models and also highlights the ongoing studies into the mechanisms of PTH actions on endochondral bone repair.Keywords
This publication has 29 references indexed in Scilit:
- Distinct roles for Hedgehog and canonical Wnt signaling in specification,differentiation and maintenance of osteoblast progenitorsDevelopment, 2006
- Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1–34) on chondrogenesis in a model of experimental fracture healingBone, 2005
- Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide TreatmentJournal of Bone and Mineral Research, 2005
- Indian hedgehog stimulates periarticular chondrocyte differentiation to regulate growth plate length independently of PTHrPJournal of Clinical Investigation, 2005
- Human parathyroid hormone (1–34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femoraBone, 2005
- Intermittent parathyroid hormone (1–34) enhances mechanical strength and density of new bone after distraction osteogenesis in ratsJournal of Orthopaedic Research, 2004
- Intermittent Parathyroid Hormone Treatment Enhances Guided Bone Regeneration in Rat Calvarial Bone DefectsJournal of Craniofacial Surgery, 2004
- Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low-Dose Human Parathyroid Hormone (1–34)Journal of Bone and Mineral Research, 2002
- Osteoblast Apoptosis and Bone TurnoverJournal of Bone and Mineral Research, 2001
- Intermittent Parathyroid Hormone (1–34) Treatment Increases Callus Formation and Mechanical Strength of Healing Rat FracturesJournal of Bone and Mineral Research, 1999